Slide 1: BIO Corporate Presentation
BIO Corporate Presentation Quan Vu, CFO/CBO BIO International 2023
Slide 2: Forward Looking Statements and Disclaimer
2 2BIO Corporate Presentation Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on information currently available to manageme
Slide 3: Ocugen is a Biotech Company Focused on Novel Gene/Cell Therapies and Vaccines
3 3BIO Corporate Presentation Ocugen is a Biotech Company Focused on the Development of Novel Gene/Cell Therapies and Vaccines Mission: to develop cutting-edge innovations for people facing serious disease and conditions with a commitment to ensuring global market access Founded: 2013 Headquarters:
Slide 4: Leveraging First-in-Class Platforms to Address Serious Unmet Medical Needs
4 4BIO Corporate Presentation Through Courageous Innovation, We are Leveraging Our First- in-Class Platforms to Address Serious Unmet Medical Needs Modifier Gene Therapy Platform First-in-Class Ø Therapeutic Focus: inherited retinal diseases and larger blindness diseases with unmet need Ø Differenti
Slide 5: Modifier Gene Therapy Platform & OCU400
Modifier Gene Therapy Platform & OCU400 Breakthrough technology designed to address many rare and complex diseases that affect millions
Slide 6: Inherited Retinal Diseases Have a High Prevalence Rate and Many Associated Genes
6 6BIO Corporate Presentation Inherited Retinal Diseases Have a High Prevalence Rate and Involve Many Associated Genes 2 million >300 genes IRD 1.6 million >100 genes RP ~120,000 >25 genes LCA ~110,000 ~15,000~400,000 G on g et a l, 2 0 21 IRD, inherited retinal degeneration; LCA, Leber congenital a
Slide 7: Modifier Gene Therapy Can Address Multiple Genetic Defects with a Single Product
7 7BIO Corporate Presentation Modifier Gene Therapy Can Potentially Address Multiple Genetic Defects with a Single, Gene Agnostic Product Modifier Gene Therapy a “master gene regulator” to modify the expression of many genes and gene-networks; current single-gene focus impractical Improved visual ou
Slide 8: OCU400: Phase 1/2 Study Examines Safety and Exploratory Efficacy Endpoints
8 8BIO Corporate Presentation OCU400: Phase 1/2 Study Examines Safety and Exploratory Efficacy Endpoints, with Adult RP Enrollment Completed LCA, Leber congenital amaurosis; RP, retinitis pigmentosa Study Overview Clinical Trials.gov Identifier: NCT05203939 Safety of Subretinal Administration of OCU
Slide 9: OCU400: Positive Preliminary Efficacy Results in MLMT
9 9BIO Corporate Presentation OCU400: Ongoing Phase 1/2 Trial Showed Positive Preliminary Efficacy Results in MLMT Total Subjects for Analyses (N=7); Pooled Analyses Subjects with 9-Months Follow-Up: Cohort 1, N=3 Subjects with 6-Months Follow-Up: N=1 from Cohort 1 and N=3 from Cohort 2 Total Subjec
Slide 10: OCU400: Positive Preliminary Efficacy Results in BCVA Score
10 10BIO Corporate Presentation OCU400: Ongoing Phase 1/2 Trial Showed Positive Preliminary Efficacy Results in BCVA Score Total Subjects for Analyses (N=7) Subjects with 9-Months Follow-Up: Cohort 1, N=3 Subjects with 6-Months Follow-Up: N=1 from Cohort 1 and N=3 from Cohort 2 Improvement ≥ 8 Lette
Slide 11: Phase 3 Trial Initiation for OCU400 Expected at End of 2023
11 11BIO Corporate Presentation Phase 3 Trial Initiation for OCU400 Expected at End of 2023, with Potential Approval and Launch in Late 2025/Early 2026 Ø Phase 3 plan: meet regulatory agencies in 3Q 2023 to potentially finalize program and overall package Ø LCA and pediatric patients: enrollment con
Slide 12: OCU500 Inhalation Vaccine Series
OCU500 Inhalation Vaccine Series OCU500: COVID-19 OCU510: Flu OCU520: COVID-19 + Flu Combination
Slide 13: OCU500 Series: Next-Generation Inhalation Vaccine Candidates
13 13BIO Corporate Presentation OCU500 Series: Next-Generation Inhalation Vaccine Candidates Can Potentially Enhance Durability and Reduce Transmission OCU500 A bivalent COVID-19 vaccine OCU510 A seasonal quadrivalent flu vaccine OCU520 A combination quadrivalent flu and bivalent COVID19 vaccine Foc
Slide 14: OCU400 & OCU500 Series are Ocugen's Transformational Steps
14 14BIO Corporate Presentation OCU400 & OCU500 Series are Ocugen’s Transformational Steps to Becoming a Fully-Integrated, Patient-Centric Company… Focused on Vaccines in Support of Public Health, and Gene and Cell Therapies Targeting Unmet Medical Needs Through Courageous Innovation